Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000273629 | SCV000334139 | uncertain significance | not provided | 2015-08-11 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000695408 | SCV000823905 | likely benign | Duchenne muscular dystrophy | 2024-11-06 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002392799 | SCV002701276 | uncertain significance | Cardiovascular phenotype | 2021-05-28 | criteria provided, single submitter | clinical testing | The p.R49H variant (also known as c.146G>A), located in coding exon 3 of the DMD gene, results from a G to A substitution at nucleotide position 146. The arginine at codon 49 is replaced by histidine, an amino acid with highly similar properties. Based on data from gnomAD, the A allele has an overall frequency of 0.003% (7/204516) total alleles studied, with 2 hemizygotes observed. The highest observed frequency was 0.016% (3/18900) of African/African-American alleles. This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV002494825 | SCV002780774 | uncertain significance | Becker muscular dystrophy; Duchenne muscular dystrophy; Dilated cardiomyopathy 3B | 2021-10-12 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000273629 | SCV003829477 | uncertain significance | not provided | 2020-08-21 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001828187 | SCV002092932 | uncertain significance | Becker muscular dystrophy; Duchenne muscular dystrophy; Cardiomyopathy; Dystrophin deficiency | 2020-04-21 | no assertion criteria provided | clinical testing |